Ann: Half Yearly Report and Accounts, page-58

I hear you but try this though

18 million in the bank - EV 58 million, no CR for a year

First sales this FY

Clear runway to UK private market

Clean sweep of management with entirely new team with deep expertise and connections in the radiopharma market

No real advances in treatment of ca pancreas, and this is adjuvant to chemo in any case. Main competitor is EBR

Chance of FDA approval for cholangio, chance of FDA allowing smaller than expected RCT for LAPC

I guess if the company goes from 90k sales this year to, say, 2.5 million next FY (100 doses) what does that mean for the share price?

And one of the people asking questions on the last business update was a Swiss fund manager, so maybe some sprouts of interest.